Monthly Prescribing Reference

Toujeo Max SoloStar Gets FDA Approval for Patients With Diabetes

Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...
Business Insider

FDA approves Toujeo® Max SoloStar®

BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo® (insulin glargine 300 Units/mL) Max SoloStar®, the highest capacity long-acting ...
equities

Sanofi Gets FDA Approval for Highest Capacity Long-Acting Insulin Pen

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...
Healio

FDA approves high-capacity insulin glargine pen

The FDA approved a 900-unit insulin glargine pen, the highest capacity long-acting insulin pen on the market in the U.S., Sanofi announced in a press release. The new insulin glargine (Toujeo) Max ...
Seeking Alpha

FDA OKs Sanofi's long-acting insulin pen Toujeo Max SoloStar

The FDA approves Sanofi's (NASDAQ:SNY) Toujeo (insulin glargine 300 Units/mL) Max SoloStar. The product holds 900 Units of Toujeo and can deliver up to 160 Units in a single injection. The company ...
FierceBiotech

Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...
Monthly Prescribing Reference

Toujeo Approved for Pediatric Patients With Diabetes

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...
News Medical

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve ...
FiercePharma

Sanofi launches fast-acting, high-concentration insulin med Toujeo in the U.K.

A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi ($SNY) announced the availability of the long-acting basal ...
clinicaladvisor.com

Toujeo Approved for Pediatric Patients With Diabetes

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...
Reuters

FDA Approves Toujeo® Max Solostar®

Israel launched large-scale strikes against Iran on Friday, saying it had attacked nuclear facilities and missile factories and killed a swathe of military commanders in what could be a prolonged ...